Endeavour Vision

Kestra Medical Technologies develops and commercializes wearable medical devices and digital health solutions for cardiovascular care. The company provides monitoring, data collection, and therapeutic intervention to protect at-risk patients, with real-time and retrospective analysis. Its Cardiac Recovery System platform integrates monitoring, therapy, digital health tools, and patient support into a single solution, anchored by the ASSURE wearable cardioverter defibrillator designed to prevent sudden cardiac death and aid cardiac recovery. Kestra aims to transform patient outcomes in cardiovascular disease through intuitive, connected technologies.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Virtual Incision is a medical technology company focused on developing innovative robotic-assisted surgical devices, specifically targeting colon resection. The company has created the MIRA (Miniaturized In vivo Robotic Assistant) Platform, which is a pioneering miniaturized surgical robotic support device. This platform allows for efficient operating room setups in minutes, eliminating the need for cumbersome equipment handling such as draping or docking. By enhancing the surgical process, Virtual Incision aims to improve clinical outcomes while also addressing healthcare costs, positioning itself as a leader in the field of robotic-assisted surgery.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, specializing in the development of bio-engineered surgical implants aimed at promoting new tissue growth and aiding in connective tissue repair. Founded in 2016, the company focuses on its innovative Bridge-Enhanced ACL Repair technology, which serves as an alternative to traditional anterior cruciate ligament (ACL) reconstruction. This technology provides surgeons with a method to restore the normal anatomy and function of the knee for patients who have experienced ACL injuries, offering a promising option for recovery and rehabilitation.

HealthJoy is a healthcare technology company that provides a benefits experience and care navigation platform designed to simplify healthcare for employees and reduce costs for employers. Its AI-driven virtual assistants help users find cost-effective care options, access doctors and insurance experts, and compare care choices. The platform integrates a company's existing benefits to deliver a personalized digital benefits wallet and supports claims, health savings accounts, and prescription management. It offers on-demand online medical consultations, live healthcare concierges, and Rx savings, enabling employees to become informed healthcare shoppers. By streamlining benefits utilization and guidance, HealthJoy aims to improve employee satisfaction and contain benefit-related expenditures. The company is based in Chicago, Illinois.

IntelyCare is a digital healthcare workforce platform that combines a gig-model mobile app with data-driven analytics to fill nursing shifts at post-acute facilities, long-term care communities, home care agencies, and rehab hospitals. The platform enables nursing professionals to view, browse, and select shifts while automating scheduling, forecasting staffing needs, and verifying licenses, helping facilities optimize staffing, reduce burnout, and improve productivity.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Kenbi is a nurse-centric outpatient care company focused on enhancing the delivery of healthcare services. It provides outpatient care management aimed at supporting nurses and addressing gaps in the healthcare system. By leveraging technology, collegial organizational structures, and human-centric design, Kenbi organizes local care teams to deliver a range of outpatient and at-home services. These services include medical care covered by insurance, as well as household assistance, guidance, and companionship for patients. The company's approach is designed to reduce the time healthcare practitioners spend on bureaucratic tasks, allowing them to focus more on patient care and improving the overall experience for patients and their families.

Virtual Incision is a medical technology company focused on developing innovative robotic-assisted surgical devices, specifically targeting colon resection. The company has created the MIRA (Miniaturized In vivo Robotic Assistant) Platform, which is a pioneering miniaturized surgical robotic support device. This platform allows for efficient operating room setups in minutes, eliminating the need for cumbersome equipment handling such as draping or docking. By enhancing the surgical process, Virtual Incision aims to improve clinical outcomes while also addressing healthcare costs, positioning itself as a leader in the field of robotic-assisted surgery.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Inbrace is a medical device company focused on revolutionizing orthodontic treatment with its innovative device that aligns teeth discreetly behind the teeth. This system utilizes patented self-guiding technology to apply continuous forces, allowing for gentle teeth correction while minimizing discomfort and reducing the frequency of dental visits compared to traditional methods. Inbrace aims to enhance patient confidence and satisfaction by addressing common concerns associated with orthodontic treatment. The company incorporates digital treatment planning, computer modeling, and direct digital manufacturing to provide a scalable, personalized solution that meets the diverse needs of orthodontic patients. With its FDA registration, Inbrace is positioned to disrupt the orthodontics market and drive practice growth for dental clinicians.

Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

SOPHiA GENETICS is a healthcare technology company specializing in data-driven medicine. It offers the SOPHiA DDM™ Platform, a cloud-based SaaS solution that analyzes complex multimodal datasets from various diagnostic modalities to generate insights. With over 780 global clients, including hospitals, laboratories, and biopharma institutions across three continents, the company aims to make data-driven medicine the standard of care in healthcare and life sciences research.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Polares Medical S.A. is a medical device company headquartered in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for the treatment of mitral valve regurgitation. Its proprietary trans-catheter mitral valve system is designed to replace the posterior leaflet of the mitral valve with a prosthetic leaflet, allowing for hemi-replacements that improve coaptation with the native anterior leaflet. This novel approach aims to reduce or eliminate mitral valve regurgitation, addressing a significant medical need for affected patients.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

IntelyCare is a digital healthcare workforce platform that combines a gig-model mobile app with data-driven analytics to fill nursing shifts at post-acute facilities, long-term care communities, home care agencies, and rehab hospitals. The platform enables nursing professionals to view, browse, and select shifts while automating scheduling, forecasting staffing needs, and verifying licenses, helping facilities optimize staffing, reduce burnout, and improve productivity.

Nuvaira, Inc. is a medical device company based in Minneapolis, Minnesota, focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). Founded in 2008, Nuvaira specializes in a novel catheter-based Lung Denervation System that aims to address airway nerve hyperactivity by targeting the parasympathetic innervation of the lungs. This minimally invasive procedure is designed to improve lung function, enhance exercise capacity, and elevate the quality of life for patients suffering from chronic respiratory conditions. With a commitment to advancing treatment options, Nuvaira seeks to reduce the clinical consequences associated with neural hyperactivity in conditions such as COPD and asthma.

Polares Medical S.A. is a medical device company headquartered in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for the treatment of mitral valve regurgitation. Its proprietary trans-catheter mitral valve system is designed to replace the posterior leaflet of the mitral valve with a prosthetic leaflet, allowing for hemi-replacements that improve coaptation with the native anterior leaflet. This novel approach aims to reduce or eliminate mitral valve regurgitation, addressing a significant medical need for affected patients.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients. Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly cost effective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.

Vertiflex Inc., established in 2005 and headquartered in Carlsbad, California, is a medical device company specializing in minimally invasive spinal surgery technologies. The company's primary product is the Superion Interspinous Spacer, a titanium implant designed to treat moderate lumbar spinal stenosis by fitting between the spinous processes in the lumbar spine. This motion-preserving solution offers an indirect decompression system, providing an alternative treatment option for patients with lumbar stenosis who may not require traditional spine surgery. As of June 11, 2019, Vertiflex Inc. operates as a subsidiary of Boston Scientific Corporation.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, focused on revolutionizing drug delivery and addiction management. Founded in 2003, the company specializes in the development of SmartStop, a digital nicotine replacement therapy that employs a wearable device to deliver programmable, transdermal drug therapy. This innovative system is designed to tailor the timing and dosage of nicotine while providing real-time behavioral support to help users manage addiction and smoking cessation effectively. Chrono Therapeutics aims to address the challenges associated with smoking addiction through its advanced technology, which seeks to achieve optimal clinical outcomes and improve the overall quality of life for users. The company's leadership team brings extensive experience in product development, research and development, and navigating regulatory pathways, positioning Chrono Therapeutics as a key player in the smoking cessation market.

EndoStim is a medical device company specializing in neurostimulation solutions for treating gastro-esophageal reflux disease (GERD). Its flagship product, a microstimulator, targets the lower esophageal sphincter muscle to restore normal function and provide long-term reflux control. EndoStim distributes its products globally and is headquartered in Dallas, Texas.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

ReShape Lifesciences is a medical device company focused on technologies to treat obesity and metabolic diseases. The company develops and commercializes products designed to provide less invasive options for weight loss, including the Lap-Band System, an adjustable gastric banding device for long-term obesity management. It also has the ReShape Vest system, an investigational laparoscopically implanted device that wraps around the stomach and is designed to support weight loss without permanent changes to the GI tract; the Vest is primarily marketed outside the United States. The company traces its origins to EnteroMedics and adopted the ReShape Lifesciences name in 2017. It is headquartered in San Clemente, California, and operates in multiple international markets.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Founded in France in 2008, Kobojo specializes in developing social games and applications for mid-core players. Their multi-platform games feature hand-drawn two-dimensional graphics, offering an artistic experience while facilitating gameplay with friends on various social networks.

SOPHiA GENETICS is a healthcare technology company specializing in data-driven medicine. It offers the SOPHiA DDM™ Platform, a cloud-based SaaS solution that analyzes complex multimodal datasets from various diagnostic modalities to generate insights. With over 780 global clients, including hospitals, laboratories, and biopharma institutions across three continents, the company aims to make data-driven medicine the standard of care in healthcare and life sciences research.

Amplidata is a technology company specializing in advanced storage solutions that significantly enhance data reliability and efficiency. Founded in 2008 by Wim De Wispelaere and Wouter Van Eetvelde, the company has developed the Amplidata Distributed Storage System, which utilizes a patent-pending BitSpread encoding technology. This innovative approach provides a storage alternative that is ten thousand times more reliable than traditional RAID systems while requiring three times less storage and power, ultimately reducing costs by five times. Amplidata's solutions are designed to address the limitations of conventional high-capacity disk systems, improving performance and minimizing error rates. Their offerings, including the AmpliStor software-defined storage system, cater to enterprises seeking scalable private and public cloud storage solutions. With operational headquarters in Belgium and R&D facilities in both Belgium and Egypt, Amplidata serves a global market, including sales and support across Europe and North America.

Quid, Inc. is a technology company based in San Francisco, California, with additional offices in New York and London. Founded in 2006, Quid develops a platform that enables users to search, analyze, and visualize collective intelligence derived from written language. Its software specializes in text-based data analysis, utilizing artificial intelligence and natural language processing to uncover insights from vast datasets, including patents, news articles, and blog posts. Quid's proprietary algorithms facilitate the identification of patterns and connections, allowing non-technical users in various sectors, such as marketing, consulting, technology, healthcare, and finance, to independently access and derive meaningful insights from high-value information. In January 2020, Quid merged with NetBase Solutions, forming a combined entity known as Netbase Quid.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Spartoo is a European online retailer based in Grenoble, France, specializing in the sale of footwear and fashion items. Founded in 2006, the company offers an extensive range of products, including shoes for men, women, and children, such as trainers, boots, sandals, and various styles of footwear. In addition to shoes, Spartoo also sells ready-to-wear apparel, leather goods, and related accessories, providing a comprehensive shopping experience for its customers. The company's e-commerce platform serves markets in several countries, including Germany, England, Italy, and Spain, as well as the United Kingdom and its offshore islands.

Amplidata is a technology company specializing in advanced storage solutions that significantly enhance data reliability and efficiency. Founded in 2008 by Wim De Wispelaere and Wouter Van Eetvelde, the company has developed the Amplidata Distributed Storage System, which utilizes a patent-pending BitSpread encoding technology. This innovative approach provides a storage alternative that is ten thousand times more reliable than traditional RAID systems while requiring three times less storage and power, ultimately reducing costs by five times. Amplidata's solutions are designed to address the limitations of conventional high-capacity disk systems, improving performance and minimizing error rates. Their offerings, including the AmpliStor software-defined storage system, cater to enterprises seeking scalable private and public cloud storage solutions. With operational headquarters in Belgium and R&D facilities in both Belgium and Egypt, Amplidata serves a global market, including sales and support across Europe and North America.

Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associes Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization. Oncoethix founders have an unsurpassed track record in identifying and bringing oncology leads to global markets. Dr. Cvitkovic, Chief Scientific Officer for Oncoethix, led the clinical development of single agent and combination regimens for cisplatin, vindesine, bleomycin, navelbine, and, more recently, irinotecan, oxaliplatin, docetaxel, and trabectedin, first as an academic investigator and then through a specialized oncology clinical research organization. Prior to founding Oncoethix and assuming responsibilities as Chief Operating Officer, Dr. Noel had co-founded another oncology drug development company which in-licensed oxaliplatin as its first portfolio product and subsequently identified, evaluated, and in-licensed novel agents for several clients. Additionally, Dr. Noel has developed expedited registration strategies for many cancer drugs and registration files for a few of these. Dr. Herait managed clinical development of irinotecan, from Phase 1 through Phase 3, while at Rhone Poulenc Rorer and subsequently, as a consultant, managed clinical studies for several novel cancer drugs. Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development. Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Amplidata is a technology company specializing in advanced storage solutions that significantly enhance data reliability and efficiency. Founded in 2008 by Wim De Wispelaere and Wouter Van Eetvelde, the company has developed the Amplidata Distributed Storage System, which utilizes a patent-pending BitSpread encoding technology. This innovative approach provides a storage alternative that is ten thousand times more reliable than traditional RAID systems while requiring three times less storage and power, ultimately reducing costs by five times. Amplidata's solutions are designed to address the limitations of conventional high-capacity disk systems, improving performance and minimizing error rates. Their offerings, including the AmpliStor software-defined storage system, cater to enterprises seeking scalable private and public cloud storage solutions. With operational headquarters in Belgium and R&D facilities in both Belgium and Egypt, Amplidata serves a global market, including sales and support across Europe and North America.

Quid, Inc. is a technology company based in San Francisco, California, with additional offices in New York and London. Founded in 2006, Quid develops a platform that enables users to search, analyze, and visualize collective intelligence derived from written language. Its software specializes in text-based data analysis, utilizing artificial intelligence and natural language processing to uncover insights from vast datasets, including patents, news articles, and blog posts. Quid's proprietary algorithms facilitate the identification of patterns and connections, allowing non-technical users in various sectors, such as marketing, consulting, technology, healthcare, and finance, to independently access and derive meaningful insights from high-value information. In January 2020, Quid merged with NetBase Solutions, forming a combined entity known as Netbase Quid.

Founded in France in 2008, Kobojo specializes in developing social games and applications for mid-core players. Their multi-platform games feature hand-drawn two-dimensional graphics, offering an artistic experience while facilitating gameplay with friends on various social networks.

Retailo is a leading European provider of prepaid and gift card services, operating a extensive network for distributing gift cards across the continent.

SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.

PneumRx, Inc. is a medical device company focused on developing minimally invasive treatments for patients with emphysema. Established in 2004 and based in Mountain View, California, the company is known for its investigational device, the RePneu Lung Volume Reduction Coil, which aims to improve lung function in individuals suffering from this chronic condition.

Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Amplidata is a technology company specializing in advanced storage solutions that significantly enhance data reliability and efficiency. Founded in 2008 by Wim De Wispelaere and Wouter Van Eetvelde, the company has developed the Amplidata Distributed Storage System, which utilizes a patent-pending BitSpread encoding technology. This innovative approach provides a storage alternative that is ten thousand times more reliable than traditional RAID systems while requiring three times less storage and power, ultimately reducing costs by five times. Amplidata's solutions are designed to address the limitations of conventional high-capacity disk systems, improving performance and minimizing error rates. Their offerings, including the AmpliStor software-defined storage system, cater to enterprises seeking scalable private and public cloud storage solutions. With operational headquarters in Belgium and R&D facilities in both Belgium and Egypt, Amplidata serves a global market, including sales and support across Europe and North America.

Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. The company was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc.

BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing innovative targeted and programmable therapeutics known as Accurins. These specialized drug delivery systems are engineered with distinct physical and chemical properties to effectively target specific cells or tissues, concentrating therapeutic agents at the disease site to improve treatment efficacy while reducing adverse effects on healthy tissues. BIND's primary focus is on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with leading biopharmaceutical firms, such as Amgen, Pfizer, and AstraZeneca, to create Accurins utilizing their therapeutic payloads. Through its medicinal nanoengineering platform, BIND Therapeutics aims to advance its own pipeline and forge strategic partnerships in the field of cancer treatment.

CXignited is a company that sets a new standard in Customer Experience (CX) by integrating product, people, and brand passion. It offers the ShopCX Cloud Platform, a cloud-based pervasive computing solution that facilitates product digitization and authentication. Through advanced technologies such as RFID, beacons, and the Internet of Things (IoT), CXignited streams shop floor and unified commerce information intelligence, allowing luxury retailers and global brands to gain a comprehensive, real-time view of in-store engagement. The platform enhances localization, personalization, and digitalization across various channels, catering specifically to the needs of the luxury retail sector.

Spartoo is a European online retailer based in Grenoble, France, specializing in the sale of footwear and fashion items. Founded in 2006, the company offers an extensive range of products, including shoes for men, women, and children, such as trainers, boots, sandals, and various styles of footwear. In addition to shoes, Spartoo also sells ready-to-wear apparel, leather goods, and related accessories, providing a comprehensive shopping experience for its customers. The company's e-commerce platform serves markets in several countries, including Germany, England, Italy, and Spain, as well as the United Kingdom and its offshore islands.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Molecular Partners is a clinical-stage biopharmaceutical company dedicated to advancing modern medicine through the development of innovative therapies. The company specializes in a novel class of small protein therapeutics known as DARPin therapeutics, which are designed to target serious diseases, including cancer and sight-threatening disorders. Molecular Partners' product pipeline is organized into three primary areas: ophthalmology, focusing on therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, which includes DARPin candidates that feature unique mechanisms of action; and additional therapeutic areas. The firm's commitment to developing potent and versatile treatments positions it at the forefront of biopharmaceutical innovation.

Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of novel anti-infectives aimed at women's health. Founded in 2008, Lumavita focuses on addressing infections that affect women, with key products including FemiFect, an antibiotic designed to treat vaginitis caused by various pathogens, and SPK-601, which targets human papilloma virus (HPV) and herpes simplex virus (HSV). The company operates as a subsidiary of Shogoo Pharmaceuticals KK and distributes its products through a network of distributors. Lumavita AG was previously known as Shogoo Pharmaceuticals, AG before rebranding in 2007.

CommProve, established in 1996, specializes in real-time Quality of Service (QoS) monitoring for wireless networks. The company, founded by experts in network operations and software engineering, offers a platform that collects, analyzes, and integrates network usage data from various mobile networks. This enables mobile network operators to gain real-time insights into their operations, helping them control financial performance, quality of experience, and network performance.

Retailo is a leading European provider of prepaid and gift card services, operating a extensive network for distributing gift cards across the continent.

Retailo is a leading European provider of prepaid and gift card services, operating a extensive network for distributing gift cards across the continent.

Molecular Partners is a clinical-stage biopharmaceutical company dedicated to advancing modern medicine through the development of innovative therapies. The company specializes in a novel class of small protein therapeutics known as DARPin therapeutics, which are designed to target serious diseases, including cancer and sight-threatening disorders. Molecular Partners' product pipeline is organized into three primary areas: ophthalmology, focusing on therapies for retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, which includes DARPin candidates that feature unique mechanisms of action; and additional therapeutic areas. The firm's commitment to developing potent and versatile treatments positions it at the forefront of biopharmaceutical innovation.

CXignited is a company that sets a new standard in Customer Experience (CX) by integrating product, people, and brand passion. It offers the ShopCX Cloud Platform, a cloud-based pervasive computing solution that facilitates product digitization and authentication. Through advanced technologies such as RFID, beacons, and the Internet of Things (IoT), CXignited streams shop floor and unified commerce information intelligence, allowing luxury retailers and global brands to gain a comprehensive, real-time view of in-store engagement. The platform enhances localization, personalization, and digitalization across various channels, catering specifically to the needs of the luxury retail sector.

EndoArt is a synthetic implant that treats corneal edema by establishing a new form of corneal availability, hence protecting vision and restoring function.

EndoArt is a synthetic implant that treats corneal edema by establishing a new form of corneal availability, hence protecting vision and restoring function.

CXignited is a company that sets a new standard in Customer Experience (CX) by integrating product, people, and brand passion. It offers the ShopCX Cloud Platform, a cloud-based pervasive computing solution that facilitates product digitization and authentication. Through advanced technologies such as RFID, beacons, and the Internet of Things (IoT), CXignited streams shop floor and unified commerce information intelligence, allowing luxury retailers and global brands to gain a comprehensive, real-time view of in-store engagement. The platform enhances localization, personalization, and digitalization across various channels, catering specifically to the needs of the luxury retail sector.